文献速递胸部肿瘤放疗

肺癌野内复发再程高剂量放疗:RETHO二期前瞻试验结果

High-Dose REirradiation for In-Field Recurrent Lung Cancer in the THOrax (RETHO): Outcomes of a Phase 2 Prospective Clinical Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-12-20

RETHO二期前瞻试验纳入64例胸部复发肺癌患者(60例可分析),再程放疗≥45 Gy10 EQD2,中位随访26.5个月,中位总生存30.1个月,局部控制28.2个月,无病生存13.6个月,3级毒性20%,无4-5级毒性。

要点

  • 胸部复发肺癌再程高剂量放疗中位OS达30.1个月,高于12个月的研究假设。
  • 再程放疗局部控制28.2个月,无病生存13.6个月,疗效良好。
  • 3级毒性20%,最常见为肺炎(12%),未观察到4-5级毒性。

核心结论

  • 胸部复发肺癌再程高剂量放疗有效,中位OS达30.1个月,高于研究设定的12个月假设。
  • 再程放疗获得良好局部控制(28.2个月)和无病生存(13.6个月),毒性较低。

研究设计与样本

  • 前瞻性二期临床试验,2018至2022年纳入64例胸部复发肺癌患者,60例纳入分析。
  • 入组标准为肿瘤距既往放疗50 Gy10 EQD2等剂量线<5 cm的边际或野内复发,再程放疗剂量≥45 Gy10 EQD2。
  • 主要终点为中位总生存,次要终点为局部控制、无病生存和毒性。

主要发现

  • 首次放疗中位剂量68 Gy10 EQD2,再程放疗中位PTV为106 cc,50例患者当前PTV与既往PTV重叠。
  • 38例(63%)采用常规分割再程放疗(中位剂量53 Gy10),22例(37%)采用立体定向体部放疗(中位剂量77 Gy10)。
  • 中位随访26.5个月,中位OS 30.1个月,局部控制28.2个月,无病生存13.6个月。
  • 3级毒性12例(20%),最常见为肺炎(12%),未记录到4-5级毒性。

关键数值与推荐

  • 再程放疗剂量≥45 Gy10 EQD2,靶区为距既往放疗50 Gy10 EQD2等剂量线<5 cm的胸部复发肿瘤。
  • 常规分割再程放疗中位剂量53 Gy10,立体定向体部放疗中位剂量77 Gy10。

临床怎么用

  • 对既往放疗后胸部边际或野内复发的肺癌患者,可考虑再程高剂量放疗,需满足肿瘤距既往50 Gy10 EQD2等剂量线<5 cm。
  • 再程放疗可采用图像引导调强放疗或容积旋转调强放疗,根据临床情况选择常规分割或立体定向体部放疗。
  • 治疗中需关注肺炎等3级毒性,本方案未观察到4-5级毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Locoregional failures after (chemo)radiation therapy for primary lung cancer account for 30% of relapses. Reirradiation in this setting is challenging. To evaluate the outcome after thoracic reirradiation with radical doses, a prospective phase 2 trial was conducted for marginal or in-field recurrences of lung cancer. METHODS AND MATERIALS: The goal of this study was to treat recurrent lung cancer with high-dose (chemo)radiation therapy to reach a median overall survival (OS) of 12 months. Patients with recurrent lung cancer in the thorax (tumor <5 cm from 50 Gy10 Equivalent Dose of 2 Gy per fraction [EQD2] isodose line of previous radiation therapy) were reirradiated with ≥45 Gy10 EQD2. The secondary endpoints were local control (LC), disease-free survival (DFS), and toxicity. RESULTS: From 2018 to 2022, 64 patients were included, of whom 60 were analyzed. The median dose of the first radiation therapy course was 68 Gy10 EQD2. All patients were reirradiated using image guided intensity modulated radiation therapy or volumetric modulated arc therapy: 38 patients (63%) using conventional fractionated radiation therapy (median dose 53 Gy10) and 22 (37%) using stereotactic body radiation treatment (median dose 77 Gy10). Median reirradiation planning target volume (PTV) was 106 cc. In 50 patients, the current PTV overlapped with the previous PTV. After a median follow-up of 26.5 months, median OS was 30.1 months, LC was 28.2 months, and DFS was 13.6 months. No grade 4-5 toxicities were registered. Grade 3 toxicities occurred in 12 patients (20%); the most common was pneumonitis (12%). CONCLUSIONS: This trial showed that high-dose thoracic reirradiation for recurrent lung cancer is effective and achieved a good OS higher than our null hypothesis. It resulted in good LC and DFS with low toxicity.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Cammareri E, Duijm M, Granton PV, et al. High-Dose REirradiation for In-Field Recurrent Lung Cancer in the THOrax (RETHO): Outcomes of a Phase 2 Prospective Clinical Trial. Int J Radiat Oncol Biol Phys. 2025. PMID: 41429403. doi:10.1016/j.ijrobp.2025.12.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。